Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography - Wikidata - wikimedia - TriplyDB

Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography

Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography

http://www.wikidata.org/entity/Q27640105

about

Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2 Structures of rhodopsin kinase in different ligand states reveal key elements involved in G protein-coupled receptor kinase activation Structural basis for the autoinhibition of focal adhesion kinase FAK and paxillin, two potential targets in pancreatic cancer The role of Eph receptors in lens function and disease A Cell Biologist's Field Guide to Aurora Kinase Inhibitors Two TPX2-dependent switches control the activity of Aurora A Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors Crystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG Conformation Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain Crystal Structure of Human Aurora B in Complex with INCENP and VX-680 Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C EPHA2 is associated with age-related cortical cataract in mice and humans A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases Focal adhesion kinase: in command and control of cell motility The cellular geography of aurora kinases Crystal structure of the FERM domain of focal adhesion kinase.Adaptability in protein structures: structural dynamics and implications in ligand design.Organization and post-transcriptional processing of focal adhesion kinase gene.Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool Identification of FAK substrate peptides via colorimetric screening of a one-bead one-peptide combinatorial library.How focal adhesion kinase achieves regulation by linking ligand binding, localization and action A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis.The target discovery process.Aurora A and B kinases as targets for cancer: will they be selective for tumors?An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.Dynamics of protein kinases: insights from nuclear magnetic resonance.Aurora A kinase (AURKA) in normal and pathological cell division.Analysis of the calcium-dependent regulation of proline-rich tyrosine kinase 2 by gonadotropin-releasing hormone Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B Tie2 and Eph receptor tyrosine kinase activation and signaling.Focal adhesion kinase and p53 signal transduction pathways in cancer.Targeting FAK in human cancer: from finding to first clinical trials.A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.

P2860

Q24318313-1FE04657-6699-4F68-9B57-BA194017D4AC Q24657590-4FBAD4D0-9C4A-4922-AF9F-E4E47F91673F Q24678318-7A8699E9-DDA3-4468-AD9D-2DCEEF46DC30 Q26765360-D60F334A-5CD5-41DE-8971-AEB1DC02DE51 Q27007359-FADE72DE-7869-461C-9146-49CC46CAE0DD Q27308125-0578A5B9-8473-4E10-B660-5B95B80E8889 Q27437614-A937CA47-6B1A-4326-A572-6FE97D1F8D48 Q27648916-80C1DBFE-98CF-4F22-86F1-C11C5552B0E3 Q27652985-81F3F0D0-397E-46D5-9E49-43B81D9A3681 Q27653949-3540C002-FC0C-4099-B7FD-25D7ACCA67EC Q27663479-AE953347-FFEA-45E6-B482-B535BC59C126 Q27671676-D5FD4FDB-EE5F-4538-95E7-4ACA77D0C7BF Q27675279-1ABB9E01-F086-46B0-B24E-AAF25E57FD4B Q27684168-B291A90C-DA2A-402C-8DB1-FFE786CB00F1 Q28277516-0E3CFB2B-473C-4614-A187-96575B3FC7DD Q28475827-F990C21D-25CD-46F5-84E5-7AC3C75018EF Q28590498-29346507-0D4D-47AA-903B-979B25C1E682 Q29615192-1EE4A8F6-01C2-472D-A822-C1632F7EACB5 Q29617749-3F340F78-F7BC-47C0-AF7F-64D201938819 Q30160113-02C21666-B3BE-4F33-9FEF-8F9C4BB9ECAE Q30357974-BD1F6438-697F-4ECD-81F0-218528539094 Q33252921-FCDFA014-601E-4A72-9DE4-4FA01B75A6E4 Q33491567-B0DCE24F-8E8D-4015-9270-65AB4FC4F9B9 Q33901743-CE75246C-5FB2-40CD-966D-07D90DC45B46 Q33971948-D4C3D00A-ABA1-4DE1-8B9F-D1F67859AE45 Q35569727-C4E9C057-4CC4-4148-9936-35A4860E17CE Q35597027-42739BF2-3FBF-42C1-839F-1F5D7C90926D Q35832346-DF1ADDE4-681D-4300-8D55-630CEEEFF2D4 Q36059506-4B9B06FB-F45F-4FF5-B705-969E24A46079 Q36352091-5BDE04D7-837E-4BF2-993A-C5281525EB00 Q36390162-EF8A6858-1469-435B-BEFA-13B59DF171C9 Q36420336-B6C0424D-DE0E-4953-B3DE-2510123B64A1 Q36715681-E4B5EBD1-8C07-4C6E-816A-942873B7B65E Q36971807-7950DBD2-7A74-4531-AF01-5507A955E2BB Q37285662-A09D9511-1C3C-4B0C-9E6C-3CD586FA7D0C Q37629840-7556BCE1-579B-4B74-A64F-B3D1DBBBBE99 Q37761970-EBF8C868-2BB3-44D6-B179-41089F4C4690 Q38175738-1727F284-6EB6-4353-A1AC-9125DEDE56F3 Q38799626-40D5460A-8E79-4033-A6F8-F1E62475FBA6 Q38829629-5C326937-1FF6-4CF2-A130-730011550F42

P2860

Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography

http://www.wikidata.org/entity/Q27640105

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Structures of the cancer-relat ...... rom nanovolume crystallography

@ast

Structures of the cancer-relat ...... rom nanovolume crystallography

@en

Structures of the cancer-relat ...... rom nanovolume crystallography

@nl

type

label

Structures of the cancer-relat ...... rom nanovolume crystallography

@ast

Structures of the cancer-relat ...... rom nanovolume crystallography

@en

Structures of the cancer-relat ...... rom nanovolume crystallography

@nl

prefLabel

Structures of the cancer-relat ...... rom nanovolume crystallography

@ast

Structures of the cancer-relat ...... rom nanovolume crystallography

@en

Structures of the cancer-relat ...... rom nanovolume crystallography

@nl

P1433

Q27640105-EE48735F-B0D6-4D82-86BF-9319FB439F5B

P1476

Q27640105-4DEA7450-45FF-4512-9E51-27291DB6B479

P2093

Q27640105-0439AEB1-20F1-4066-9034-09C17D01771A

Q27640105-20300CB5-CB9B-4B46-B45D-873AE4A06327

Q27640105-5114F8D9-8EC7-465D-A9C4-ED99CE7F2309

Q27640105-63B078F6-5A0D-4D1B-B03F-BFBE2631E84E

Q27640105-83171173-77E9-4DAA-8854-30C5484AA525

Q27640105-8FC81234-3F96-4742-96D8-5671594548B4

Q27640105-93DD71AE-F757-4AE9-ADDB-B0A5FE52FEF2

Q27640105-D46F0930-8318-4666-BBFA-9320945F4F73

Q27640105-D49C26B3-AE20-4955-BE1C-F0C1AD126BCC

Q27640105-DE820BC5-2CC8-48C6-BFD4-0B6F12C82D52

P304

Q27640105-6B337017-9661-4ABF-8006-5D51F0CF1BF6

P31

Q27640105-6F80F8C2-C5AC-4787-A0E9-403B82FC802C

P3181

Q27640105-A0EA0962-5F41-4421-B2FA-E052C03E0975

P356

Q27640105-5EA43D18-1E53-4141-BA10-95D8662E9934

P407

Q27640105-22428F5E-73EB-4C4F-839A-EB0FC414145D

P433

Q27640105-0041A839-A04A-4B02-BD0E-7D240B6EA0C2

P478

Q27640105-0DEBCA84-2FCB-4322-9C2E-5168B2CDF3E4

P50

Q27640105-6181396D-111F-4E23-AB37-BA667A05CF29

P577

Q27640105-EDD1717E-D866-436E-858D-5FC818AD0C87

P698

Q27640105-68E029E5-D4DF-49A8-AB00-2CD0FDBD43A2

P921

Q27640105-1CC2D656-1837-4164-94FF-94877C8EEC56

P3181

P356

S0969-2126(02)00907-3

P1433

P1476

Structures of the cancer-relat ...... rom nanovolume crystallography

@en

P2093

Bi-Ching Sang

http://www.w3.org/2001/XMLSchema#string

Christian G Nelson

http://www.w3.org/2001/XMLSchema#string

Ciarán N Cronin

http://www.w3.org/2001/XMLSchema#string

Daniel N Scheibe

http://www.w3.org/2001/XMLSchema#string

Devon A Thompson

http://www.w3.org/2001/XMLSchema#string

Duncan E McRee

http://www.w3.org/2001/XMLSchema#string

Jacek Nowakowski

http://www.w3.org/2001/XMLSchema#string

Joe Rogers

http://www.w3.org/2001/XMLSchema#string

Nikola P Pavletich

http://www.w3.org/2001/XMLSchema#string

Ronald V Swanson

http://www.w3.org/2001/XMLSchema#string

P304

1659-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3537976

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0969-2126(02)00907-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12467573

http://www.w3.org/2001/XMLSchema#string

P921

protein structure